Ranibizumab
Ranibizumab is an anti-vascular endothelial growth factor (anti-VEGF) antibody fragment administered via intravitreal injection to treat ocular conditions involving abnormal blood vessel growth and fluid leakage in the retina. It is primarily used for neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema secondary to retinal vein occlusion.
A monoclonal antibody fragment that inhibits VEGF to reduce abnormal blood vessel growth and fluid leakage in retinal diseases.
Key facts at a glance
- ATC
- S01LA04
- RxNorm
- 595060
- Generic
- Ranibizumab
- Class
- atc-s01
- Brands
- Susvimo, Byooviz, Cimerli, Nufymco, Lucentis
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection, prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 0.5 mg monthly
- Maximum
- consult physician
- Frequency
- once monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.5 mg monthly
- Maximum
- consult physician
- Frequency
- once monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.5 mg monthly
- Maximum
- consult physician
- Frequency
- once monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
7 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second third trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingavoid if possible
do not breastfeed during treatment and for at least 1 month after last dose
monitor infant for adverse effects
geriatric
elderly over 65no adjustment needed
use with caution and monitor closely for adverse reactions
regular ophthalmic examinations and monitoring for systemic effects
Use with caution and monitor for adverse effects.
pediatric_age
pediatric under 18not recommended
not recommended for use in pediatric patients
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
mild to severeno adjustment needed
no dosage adjustment required for patients with renal impairment
monitor renal function periodically
hepatic_impairment
mild to severeno adjustment needed
no dosage adjustment required for patients with hepatic impairment
monitor hepatic function periodically
Statistics and clinical data
FDA approval year
Lucentis was first approved by FDA
Drug class
Vascular endothelial growth factor inhibitor
Common uses
FDA-approved indications
Mechanism of action
Pharmacological mechanism
Treats neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
Binds to and neutralizes active forms of VEGF-A (including VEGF110), preventing VEGF from interacting with its receptors on endothelial cells. This inhibits neovascularization and reduces vascular leakage in the retina.
Administered as an intravitreal injection by a healthcare professional. Potential risks include endophthalmitis, increased intraocular pressure, and retinal detachment. Patients should be monitored regularly. Contraindicated in patients with ocular infections or hypersensitivity to the drug.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy